831 results on '"Cervantes, Andrés"'
Search Results
2. CT-based clinical-radiomics model to predict progression and drive clinical applicability in locally advanced head and neck cancer
3. Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03
4. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast progressing patients
5. Generation, Expansion, and Biobanking of Gastrointestinal Patient-Derived Organoids from Tumor and Normal Tissues
6. Association Between Quantitative and Qualitative Imaging Biomarkers and Geographic Atrophy Growth Rate
7. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
8. The role of anti-EGFR rechallenge in metastatic colorectal cancer, from available data to future developments: A systematic review
9. “Proteotranscriptomic analysis of advanced colorectal cancer patient derived organoids for drug sensitivity prediction”
10. The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practice
11. Strategies for improving detection of circulating tumor DNA using next generation sequencing
12. Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma
13. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe
14. How organoids can improve personalized treatment in patients with gastro-esophageal tumors
15. European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer
16. Napabucasin Plus FOLFIRI in Patients With Previously Treated Metastatic Colorectal Cancer: Results From the Open-Label, Randomized Phase III CanStem303C Study
17. Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery: A 5-Year Follow-up of the RAPIDO Trial
18. Adding dried distillers grains with solubles influences the rumen microbiome of meat goats fed lespedeza or alfalfa-based diets
19. Locoregional Failure During and After Short-course Radiotherapy followed by Chemotherapy and Surgery Compared to Long-course Chemoradiotherapy and Surgery – A Five-year Follow-up of the RAPIDO Trial
20. The LEGACy study: a European and Latin American consortium to identify risk factors and molecular phenotypes in gastric cancer to improve prevention strategies and personalized clinical decision making globally
21. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
22. Colorectal cancer survival: prevalence of psychosocial distress and unmet supportive care needs
23. Meta-analysis of the effects of dietary inclusion of sericea lespedeza (Lespedeza cuneata) forage on performance, digestibility, and rumen fermentation of small ruminants
24. Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data
25. Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges
26. Effect of Lactobacillus hilgardii, Lactobacillus buchneri, or their combination on the fermentation and nutritive value of sorghum silage and corn silage
27. Meta-analysis of effects of inoculation with Lactobacillus buchneri, with or without other bacteria, on silage fermentation, aerobic stability, and performance of dairy cows
28. Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study
29. Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver
30. Contributors
31. Translational epigenetics in precision medicine of colorectal cancer
32. Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer.
33. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer – Results of the international randomized RAPIDO-trial
34. Impact of perioperative transfusions and sepsis on long-term oncologic outcomes after curative colon cancer resection. A retrospective analysis of a prospective database
35. Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success
36. Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre
37. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer
38. Aurora kinases in ovarian cancer
39. The 2017 Assisi Think Tank Meeting on rectal cancer: A positioning paper
40. A phase 1b study of the MET inhibitor capmatinib combined with cetuximab in patients with MET-positive colorectal cancer who had progressed following anti-EGFR monoclonal antibody treatment
41. Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
42. Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE study
43. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer
44. Supplementary Figure S9 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
45. Supplementary Table S8 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
46. Data from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies
47. Implementation of an Educational Intervention for Gastric Cancer Awareness in the General Population in CELAC and Europe. A Strategy Proposed by the LEGACy Consortium
48. CtDNA Whole-Exome Sequencing in Pancreatic Ductal Adenocarcinoma Unveils Organ-Dependent Metastatic Mechanisms and Identifies Actionable Alterations in Fast Progressing Patients
49. Apuntes históricos relacionados al óxido nitroso, éter, cloroformo y los inicios de la anestesia inhalatoria en México.
50. Low miR200c expression in tumor budding of invasive front predicts worse survival in patients with localized colon cancer and is related to PD-L1 overexpression
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.